摘要
一项国际多中心随机对照Ⅲ期临床研究比较LV5FU2 (DeGramont方案 )及LV2 FU2 加奥沙利铂治疗晚期大肠癌的疗效 ,结果证实加有奥沙利铂者疗效较高 (总缓解率 5 0 %vs 2 1 9%。无进展存活期 8 7个月vs6 1个月 ,均具有明显统计学差异 )。在法国进行的另一项多中心对比研究也得出同样结果 (FU/FA +奥沙利铂总缓解率 5 3 % ,无病生存期 8 9个月 ,FU/FA组总缓解率 16 % ,无病生存期 5 2个月 ,均有显著性差异 )。目前 ,奥沙利铂已被确认为治疗晚期大肠癌的有效一线药。主要剂量限制性毒性为中度粒细胞减少及感觉神经障碍 ,即使使用高剂量 ,也几乎不见肾毒性。如何设计包括奥沙利铂的联合化疗方案以取得最佳治疗效果 。
An international multi center randomized phase Ⅲclinical study comparing LV 5FU 2 (De Gramont regime) vs LV 5FU 2+oxaliplatin confirmed the superiority of the oxaliplatin combination arm in the treatment of advanced colorectal cancer (CRC)(RR 50%vs 21 9%, and the PFS 8 7 m vs 6 1 m) Similar results were obtained in another multi center study in France (RR was 53%for FU/FA+oxaliplatin vs 16%for FU/FA, DFS was 8 9 m vs 5 2 m) Oxaliplatin has been recognized as one of the effective drugs for the first line therapy of advanced CRC Moderate granulocytopenia and neuro sensory symptoms were found to be the dose limiting toxicities, and renal toxicity was not encountered even if high dose was administered Further clinical studies are still on going in USA and Europe in order to define the best combination regime for advanced CRC
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1999年第6期624-630,共7页
Chinese Journal of Cancer
关键词
大肠肿瘤
草酸铂
药物疗法
Colorectal cancer
Oxaliplatin
Chemotherapy
